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Abstract
● AIM: To establish the efficacy and safety of bimatoprost 
0.03% monotherapy in glaucoma and ocular hypertension 
(OHT) patients with inadequate intraocular pressure (IOP)
on current therapy. 
● METHODS: Pre- and post-switch IOPs were analyzed for 
59 consecutive patients who were switched from current 
therapy to bimatoprost monotherapy between 2011-2015. 
Demographic information, diagnosis, and any adverse 
events were recorded. Change in IOP post-pre switch was 
analyzed using a 2-sided Student's paired t-test at the 5% 
significance level. 
● RESULTS: There was a statistically significant mean 
reduction in IOP at the first follow up visit, which was 
maintained at subsequent follow up visits for patients 
regardless of diagnosis, or pre-switch treatment (P<0.001). 
Subgroup analysis also demonstrated a statistically 
significant mean reduction in IOP when looking at OHT 
patients only, as well as patients with any diagnosis 
switched from latanoprost monotherapy to bimatoprost 
monotherapy (P<0.001).
● CONCLUSION: This is the largest independent data 
set which supports switching glaucoma patients with 
poor response to current treatment onto bimatoprost 
monotherapy before considering other adjuvant medical 
or more invasive therapy.
● KEYWORDS: glaucoma; ocular hypertension; bimatoprost; 
latanoprost
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INTRODUCTION
G laucoma is a complex neurodegenerative condition estimated to effect 64.3 million people worldwide 
in 2013, a number that is predicted to rise to 111.8 million 
by 2040[1]. The only modifiable risk factor in the treatment 
of glaucoma to date is the reduction of intraocular pressure 
(IOP)[2]. Prostaglandin analogues (PGAs; bimatoprost, 
latanoprost, Travaprost) are commonly the first line agents 
used to lower IOP in primary open angle glaucoma (POAG), 
and ocular hypertension (OHT)[3]. Although the precise 
mechanism of action of these drugs is not known, it is widely 
accepted that they act to increase aqueous outflow via two 
pathways; uveoscleral outflow increase by extracellular matrix 
remodeling[4], and trabecular outflow increase[5]. 
Meta-analyses have shown bimatoprost 0.03% to be equivalent 
in its IOP lowering efficacy when compared to Travaprost, 
or Latanoprost[6]. In recent years however, there has been a 
small, but growing body of Allergan sponsored literature[7-14], 
as well as independent studies[15-18] supporting the use of 
Bimatoprost in patients with OHT, normal tension glaucoma 
(NTG), and POAG who are deemed ‘non-responders’ on their 
current treatment. The largest independent study currently 
in the literature consisted of 46 patients with POAG or OHT 
and found no significant benefit from a switch to bimatoprost 
monotherapy[17].  
We present an independent observational study of glaucoma and 
OHT patients with inadequate IOP control on current therapy 
that were switched to bimatoprost 0.03% monotherapy.
SUBJECTS AND METHODS
Consecutive ‘non-responder’ patients with IOPs above their 
target IOP on current treatment were prospectively identified 
by the lead glaucoma consultant between July 2011 and Jan 
2015. These patients were switched from their current IOP 
lowering agent to bimatoprost 0.03% monotherapy only.
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Data collection was carried out retrospectively, through case note 
review and clinical electronic data base searches. Information 
on patient demographics, diagnosis, pre-switch treatment, pre-
switch IOP, IOP at all available post-switch clinics, as well as 
any adverse events were recorded. 
To be included patients required a minimum of one follow up 
visit; documentation of pre- and post-switch IOP recordings, 
pre-switch therapy and documentation of any adverse events. 
Any participants with active ocular disease except glaucoma 
or receiving ocular treatment which may affect the IOP were 
excluded. The structure of the study is shown in Figure 1.
This study was approved by the institutional review board and 
followed the regulations of the Personal Information Protection 
and Electronic Documents Act and the Good Clinical Practice 
Guidelines of the Declaration of Helsinki.
Change in IOP post-pre switch was analyzed using a 2-sided 
Student's paired t-test at the 5% significance level for left eye 
and then for right eye (to assess consistency).
RESULTS
Adequate follow up data for analysis was obtained for a total 
of 59 consecutive patients following the clinical records search. 
Patient demographics are detailed in Table 1. The majority of 
patients had OHT as their working diagnosis, with over half 
on monotherapy with latanoprost before being switched to 
bimatoprost. The mean pre-switch IOP for all study patients 
regardless of diagnosis was 23.4 mm Hg.
Intraocular Pressure Effects of Bimatoprost Monotherapy 
at First Follow up  The average time between switch to 
bimatoprost and the first follow up appointment was 104±44d. 
The mean reduction in IOP from pre-switch IOP at this time 
point for right eyes was: -4.24 mm Hg; 95%CI (-5.49 to -2.1); 
P<0.001 (n=58), and the mean reduction in IOP at this time 
point for left eyes was: -4.42 mm Hg; 95%CI (-5.4 to -2.45); 
P<0.001 (n=59). 
At the first follow up visit, 16 (27%) of patients were deemed 
to have unsatisfactory IOP, and were either switched to 
other therapy, or listed for selective laser trabeculoplasty. 
The remaining 33 (55.9%) patients remained on bimatoprost 
monotherapy, as their IOP was deemed satisfactory.
Subgroup Analysis
Ocular hypertension patients switched to bimatoprost  The 
mean reduction in IOP for OHT patients at first follow up 
appointment for right eyes (n=47) was -4.11 mm Hg; 95%CI (-5.62 
to -2.59); P<0.001. The mean reduction in IOP for OHT 
patients at first follow up appointment for left eyes (n=48) was 
-4.52 mm Hg; 95%CI (-5.67 to -3.37); P<0.001.
Patients switched from latanoprost monotherapy to 
bimatoprost monotherapy  For patients with any diagnosis, 
switched from latanoprost monotherapy to bimatoprost 
monotherapy (n=37), the mean reduction in IOP at first follow 
up appointment was -5.27 mm Hg; 95%CI (-6.87 to -3.67); 
P<0.001 for right eyes, and -5.27 mm Hg; 95%CI (-6.56 to 
-3.98); P<0.001 for left eyes.
Intraocular Pressure Effects of Bimatoprost Monotherapy 
at Second Follow up  Second follow up appointment data 
were available for 30 patients. The average time from switch to 
bimatoprost to second follow up appointment was 320±109d. 
The mean reduction in IOP from pre-switch IOP at this time 
point for right eyes was: -6.31 mm Hg; 95%CI (-8.58 to -4.04); 
P<0.001 (n=30), and the mean reduction in IOP at this time 
point for left eyes was: -7.95 mm Hg; 95%CI (-8.75 to -5.25); 
P<0.001 (n=30).
Table 1 Baseline characteristics of study patients                  n (%)
Characteristics Values
Age (a)
    Mean (range) 64 (42-88)
Sex
   M
   F
31 (53)
28 (47)
Race
   Caucasian
   Black
   Asian
23 (39)
24 (41)
12 (20)
Diagnosis
   OHT
   POAG
   NTG
   PAC-OHT
   PACG
43 (73)
6 (10)
4 (7)
5 (8)
1  (2)
IOP-lowering Rx
Latanoprost
Travoprost
Travoprost/Timolol combination drop
Latanoprost+Dorzolamide/Timolol combination drop
Dorzolamide+Travoprost/Timolol combination drop
Brinzolamide+Bimatoprost/Timolol combination drop
Latanoprost/Timolol combination drop 
39 (66)
11 (19)
3 (5)
2 (3)
2 (3)
1 (2)
1 (2)
Mean Pre-switch IOP (mm Hg)
  Right eye
  Left eye
23.2±4.4
23.3±3.7
Figure 1 Study structure. 
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The summary of mean IOP at each follow up visit can be 
found in Table 2.
Adverse Events  Of all patients in the study, four adverse 
events were recorded; three patients reported increased 
conjunctival hyperaemia post-switch from Travaprost, and 
treatment was discontinued. Another patient reported frequent 
headaches associated with the switch to bimatoprost, but in 
this case, these side effects were deemed minor, and the patient 
continued on bimatoprost monotherapy. 
DISCUSSION
We present the largest independent data set published to date 
following the progress of patients switched to bimatoprost 
0.03% monotherapy due to inadequate response to previous 
therapy. Our findings suggest that for some patients with 
glaucoma who fail to respond adequately to mono, dual, 
and triple medical therapy, bimatoprost 0.03% appears to 
offer statistically, and clinically significant additional IOP 
reduction. For over 55.9% of non-responder patients a switch 
to bimatoprost monotherapy provided adequate IOP response 
at first follow up. As demonstrated by our long-term follow up 
data, the initial IOP reductions seen appear to be sustained, or 
even modestly improved by 10mo.
Our subgroups analyses show that there is a statistically 
significant reduction in IOP in OHT patients who are switched 
from any current treatment to bimatoprost monotherapy. This 
is important, as the aim with OHT patients should always 
be to achieve adequate control using medical monotherapy, 
and bimatoprost appears to allow this to occur in patients not 
responding to other therapy. 
The second subgroup analysis compared latanoprost 
monotherapy to bimatoprost monotherapy in patients with a 
mixture of diagnoses; again, a statistically significant reduction 
in IOP was seen upon switch, suggesting that non-responders 
to latanoprost monotherapy should always have a trial switch 
to bimatoprost monotherapy before moving onto dual medical 
therapy, or selective laser trabeculoplasty. 
To date, latanoprost remains the most commonly prescribed 
first line PGA in patients with OHT and POAG, and this is 
confirmed by our baseline patient demographics. Incidence 
of latanoprost nonresponse has been reported to be as high as 
28.1% in the Japanese population[19]. A mixture of industry 
sponsored[9-10,13], and independent[15-16] short- and long-term 
studies have demonstrated an additional IOP lowering effect of 
bimatoprost when compared to latanoprost.
A number of reasons have been put forward for bimatoprost’s 
additional IOP lowering efficacy when compared with other 
PGAs; PGAs such as latanoprost are pro-drugs that require de-
esterification to yield an active drug. It has been speculated 
that poor de-esterification of latanoprost could explain the 
cohort of latanoprost non-responders[15]. PGAs act primarily 
via prostaglandin F2α prostanoid receptors
[20], whereas there 
is in vitro, and ex vivo evidence based on ahuman anterior 
segment model that bimatoprost acts on a distinct prostamide 
receptor in the trabecular meshwork, increasing outflow by 
approximately 40%[21].
Results from our small observational study support switching 
glaucoma patients with poor response to current treatment 
onto bimatoprost monotherapy before considering other 
adjuvant medical or more invasive therapy. The benefits of this 
approach include sustained IOP reduction on monotherapy, 
avoidance of increased cost and side effects of poly-pharmacy, 
and improved patient compliance due to simplicity of regime.
While the exact mechanisms by which Bimatoprost produces 
its additional IOP lowering effects on non-responders remains 
to be elucidated, there is a growing body of evidence that this 
prostamide appears to exhibit additional IOP lowering efficacy 
when compared to other PGAs.
Weaknesses of this study include a relatively small patient 
cohort of 59, and non-blindness of examiners to the patient’s 
treatment. It is also noted that patient compliance to a single 
medication regimen may be better than to a multi-medication 
regimen. 
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